<?xml version="1.0" encoding="UTF-8"?>
<p>With regard to ZIKV, IFN-I treatment has not been described in ZIKV patients. A recent murine model of ZIKV infection using dexamethasone-immunosuppressed mice showed that IFN-I treatment improved clinical outcomes, reducing viral load and inflammation in different visceral organs including testicles, suggesting the consideration for evaluating the effects of recombinant IFN treatment in patients at high risk for ZIKV-associated complications [
 <xref rid="B292" ref-type="bibr">292</xref>].
</p>
